Login to Your Account

Clinic Roundup

Wednesday, March 28, 2012
• Morphotek Inc., of Exton, Pa., completed enrollment in a Phase III trial (FAR-131) of farletuzumab for ovarian cancer. The randomized, double-blind trial will compare farletuzumab at two doses in combination with second-line standard of care against standard of care and placebo with a primary endpoint of progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription